This Viewpoint discusses advancements in direct reprogramming in the treatment of heart failure, diabetes, and hearing loss.
Striking a balance between public health research based on residual newborn screening blood spots and preserving parental rights to consent their use is the focus of this Viewpoint.
This Viewpoint examines federal and state syringe access policies in light of a recent HIV outbreak among injection drug users.
This Viewpoint unravels predictive analytics, a necessary component of setting clinical guidelines based on populations of patients, but stop short in estimating individual risk.
This randomized trial compared the efficacy and safety of 6 vs 24 months of warfarin treatment for preventing recurrent thromboembolism in patients with a first episode of symptomatic unprovoked pulmonary embolism.
This prospective cohort study reports that incident stroke among participants aged 45 years or older without cognitive impairment was associated with acute decline in cognitive function and also accelerated and persistent cognitive decline over 6 years.
This study uses individual participant data from the Emerging Risk Factors Collaboration to estimate reductions in life expectancy associated with cardiometabolic multimorbidity.
Using colon cancer registry data, these investigators found that in women with a mismatch repair gene mutation, hormonal factors such as age at menarche, parity, and use of hormonal contraceptives were associated with a lower risk of endometrial cancer.
This JAMA Clinical Evidence Synopsis describes the association of long-term duration vs short-term duration of vitamin K antagonist therapy among patients with venous thromboembolism.
This article analyzes diagnostic testing methods for a patient with suspected pulmonary embolism.
This From the Medical Letter article reviews the pharmacokinetics and indications for edoxaban, an oral anticoagulant for the treatment of venous thromoboembolism and prevention of stroke in patients with AF.
This analysis uses data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) national registry to report on changes in the types of treatment patients with low-risk prostate cancer received from 1990 through 2013.
Former NIH Director Harold Varmus, MD, discusses his career, cancer research, and a new role at the Weill Cornell Medical College in New York City.